/PRNewswire/ INOVIO (NASDAQ: INO) announced results from the company s novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor.
Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize.
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious.
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious.